120 related articles for article (PubMed ID: 15289727)
1. Stage III non-small-cell lung cancer treated with high-dose hyperfractionated radiation therapy and concurrent low-dose daily chemotherapy with or without weekend chemotherapy: retrospective analysis of 301 patients.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
Am J Clin Oncol; 2004 Aug; 27(4):350-60. PubMed ID: 15289727
[TBL] [Abstract][Full Text] [Related]
2. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
[TBL] [Abstract][Full Text] [Related]
3. Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Jeremić B; Miličić B; Milisavljevic S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1157-63. PubMed ID: 21640518
[TBL] [Abstract][Full Text] [Related]
4. Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: final results in 536 patients.
Jeremic B; Milicic B; Dagovic A; Aleksandrovic J; Milisavljevic S
Am J Clin Oncol; 2004 Dec; 27(6):616-25. PubMed ID: 15577441
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study.
Jeremic B; Shibamoto Y; Acimovic L; Milisavljevic S
J Clin Oncol; 1996 Apr; 14(4):1065-70. PubMed ID: 8648358
[TBL] [Abstract][Full Text] [Related]
6. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer.
Shibamoto Y; Jeremic B; Acimovic L; Milicic B; Nikolic N
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):295-300. PubMed ID: 11380214
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer.
Jeremic B; Shibamoto Y; Acimovic L; Djuric L
J Clin Oncol; 1995 Feb; 13(2):452-8. PubMed ID: 7844608
[TBL] [Abstract][Full Text] [Related]
8. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
9. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.
Jeremic B; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):303-8. PubMed ID: 8567330
[TBL] [Abstract][Full Text] [Related]
10. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
Jeremic B; Milicic B; Acimovic L; Milisavljevic S
J Clin Oncol; 2005 Feb; 23(6):1144-51. PubMed ID: 15718310
[TBL] [Abstract][Full Text] [Related]
11. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
12. Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy.
Jeremić B; Milićić B
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):426-32. PubMed ID: 17306936
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer.
Jeremic B; Shibamoto Y; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):343-8. PubMed ID: 10760429
[TBL] [Abstract][Full Text] [Related]
14. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study.
Jeremić B; Milicić B; Acimović L; Milisavljević S
J Clin Oncol; 2005 Oct; 23(28):6873-80. PubMed ID: 16192579
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients.
Jeremić B; Miličić B; Milisavljevic S
Clin Transl Oncol; 2012 Aug; 14(8):613-8. PubMed ID: 22855143
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment prognostic factors in patients with stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy.
Jeremic B; Shibamoto Y
Lung Cancer; 1995 Aug; 13(1):21-30. PubMed ID: 8528637
[TBL] [Abstract][Full Text] [Related]
17. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
18. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
19. Five-year results of a phase II trial of hyperfractionated radiotherapy and concurrent daily cisplatin chemotherapy for stage III non-small-cell lung cancer.
Keene KS; Harman EM; Knauf DG; McCarley D; Zlotecki RA
Am J Clin Oncol; 2005 Jun; 28(3):217-22. PubMed ID: 15923791
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
